Nitric oxide for inhalation in the acute treatment of sickle cell pain crisis: A randomized controlled trial

JAMA

Volumn 305, Issue 9, 2011, Pages 893-902

  Gladwin, Mark T ^a,b   Kato, Gregory J ^c   Weiner, Debra ^e   Onyekwere, Onyinye C ^f   Dampier, Carlton ^g   Hsu, Lewis ⁱ   Hagar, R Ward ^h   Howard, Thomas ^j   Nuss, Rachelle ^k   Okam, Maureen M ^e   Tremonti, Carole K ^e   Berman, Brian ^l   Villella, Anthony ^l   Krishnamurti, Lakshmanan ^b   Lanzkron, Sophie ^m   Castro, Oswaldo ^f   Gordeuk, Victor R ^f   Coles, Wynona A ^c   Peters Lawrence, Marlene ^c   Nichols, James ^c   Hall, Mary K ^d   Hildesheim, Mariana ^a,c   Blackwelder, William C ^d   Baldassarre, James ⁿ   Casella, James F ^m   more..

^a UNIVERSITY OF PITTSBURGH SCHOOL OF MEDICINE   (United States)

^b UNIVERSITY OF PITTSBURGH   (United States)

^c NATIONAL HEART LUNG AND BLOOD INSTITUTE   (United States)

^d NATIONAL INSTITUTES OF HEALTH   (United States)

^e HARVARD MEDICAL SCHOOL   (United States)

^f HOWARD UNIVERSITY HOSPITAL   (United States)

^g EMORY UNIVERSITY   (United States)

^h CHILDREN S HOSPITAL OAKLAND   (United States)

ⁱ CHILDREN'S NATIONAL MEDICAL CENTER   (United States)

^j UNIVERSITY OF ALABAMA AT BIRMINGHAM   (United States)

^k UNIVERSITY OF COLORADO SCHOOL OF MEDICINE   (United States)

^l CASE WESTERN RESERVE UNIVERSITY   (United States)

^m JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

ⁿ MALLINCKRODT PHARMACEUTICALS   (United States)

more..

Author keywords

[No Author keywords available]

Indexed keywords

HYDROXYUREA; METHEMOGLOBIN; MORPHINE; NITRATE; NITRIC OXIDE; NITRITE; OPIATE; PLACEBO;

ABNORMAL SENSATION; ACUTE CHEST SYNDROME; ADOLESCENT; ADULT; AGED; ANALGESIA; ARTICLE; BLOOD VESSEL OCCLUSIVE PAIN CRISIS; CHILD; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; DRUG TOLERABILITY; DRUG TREATMENT FAILURE; DYSPHAGIA; FAMILY DECISION MAKING; FEMALE; FEVER; FOREIGN BODY SENSATION; HEMOGLOBIN BLOOD LEVEL; HUMAN; LENGTH OF STAY; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; PAIN; PAIN ASSESSMENT; PATIENT COMPLIANCE; PATIENT DECISION MAKING; PHASE 2 CLINICAL TRIAL; PHYSICIAN ATTITUDE; PRIORITY JOURNAL; PROSPECTIVE STUDY; RANDOMIZED CONTROLLED TRIAL; SCHOOL CHILD; SICKLE CELL ANEMIA; SIDE EFFECT; TREATMENT DURATION; TREATMENT OUTCOME; VISUAL ANALOG SCALE; WALKING;

EID: 79952233719     PISSN: 00987484     EISSN: 15383598     Source Type: Journal    
DOI: 10.1001/jama.2011.235     Document Type: Article

References (47)

1. Kaul DK, Hebbel RP. Hypoxia/reoxygenation causes inflammatory response in transgenic sickle mice but not in normal mice. J Clin Invest. 2000;106(3):411-420. (Pubitemid 30655641)
2. Belcher JD, Bryant CJ, Nguyen J, et al. Transgenic sickle mice have vascular inflammation. Blood. 2003; 101(10):3953-3959. (Pubitemid 36857872)
3. Belcher JD, Marker PH, Weber JP, Hebbel RP, Vercellotti GM. Activated monocytes in sickle cell disease: potential role in the activation of vascular endothelium and vaso-occlusion. Blood. 2000;96(7):2451-2459.
4. Belcher JD, Mahaseth H, Welch TE, et al. Critical role of endothelial cell activation in hypoxia-induced vasoocclusion in transgenic sickle mice. Am J Physiol Heart Circ Physiol. 2005;288(6):H2715-H2725. (Pubitemid 40720650)
5. Platt OS. Sickle cell anemia as an inflammatory disease. J Clin Invest. 2000;106(3):337-338. (Pubitemid 30655633)
6. Frenette PS. Sickle cell vaso-occlusion: multistep and multicellular paradigm. Curr Opin Hematol. 2002;9(2):101-106. (Pubitemid 34171484)
7. Platt OS, Brambilla DJ, Rosse WF, et al. Mortality in sickle cell disease: life expectancy and risk factors for early death. N Engl J Med. 1994;330(23):1639-1644.
8. Sickle cell disease patients in US hospitals, 2004. Steiner CA, Miller JL. Healthcare Cost and Utilization Project, Agency for Healthcare Research and Quality. http://www.hcup-us.ahrq.gov/reports/statbriefs/sb21.pdf. Accessed February 7, 2011.
9. Weiner DL, Hibberd PL, Betit P, Cooper AB, Botelho CA, Brugnara C. Preliminary assessment of inhaled nitric oxide for acute vaso-occlusive crisis in pediatric patients with sickle cell disease. JAMA. 2003;289(9):1136-1142. (Pubitemid 37430328)
10. Gladwin MT, Vichinsky E. Pulmonary complications of sickle cell disease. N Engl J Med. 2008;359(21):2254-2265.
11. Vichinsky EP, Neumayr LD, Earles AN, et al; National Acute Chest Syndrome Study Group. Causes and outcomes of the acute chest syndrome in sickle cell disease. N Engl J Med. 2000;342(25):1855-1865. (Pubitemid 30419049)
12. Rees DC, Cervi P, Grimwade D, et al. The metabolites of nitric oxide in sickle-cell disease. Br J Haematol. 1995;91(4):834-837.
13. Lopez BL, Barnett J, Ballas SK, Christopher TA, Davis-Moon L, Ma X. Nitric oxide metabolite levels in acute vaso-occlusive sickle-cell crisis. Acad Emerg Med. 1996;3(12):1098-1103. (Pubitemid 26415784)
14. Head CA, Brugnara C, Martinez-Ruiz R, et al. Low concentrations of nitric oxide increase oxygen affinity of sickle erythrocytes in vitro and in vivo. J Clin Invest. 1997;100(5):1193-1198. (Pubitemid 27386304)
15. Gladwin MT, Schechter AN, Shelhamer JH, et al. Inhaled nitric oxide augments nitric oxide transport on sickle cell hemoglobin without affecting oxygen affinity. J Clin Invest. 1999;104(7):937-945. (Pubitemid 29536343)
16. Glover RE, Ivy ED, Orringer EP, Maeda H, Mason RP. Detection of nitrosyl hemoglobin in venous blood in the treatment of sickle cell anemia with hydroxyurea. Mol Pharmacol. 1999;55(6):1006-1010. (Pubitemid 29252365)
17. Morris CR, Kuypers FA, Larkin S, et al. Arginine therapy: a novel strategy to induce nitric oxide production in sickle cell disease. Br J Haematol. 2000;111(2):498-500.
18. Reiter CD, Wang X, Tanus-Santos JE, et al. Cell-free hemoglobin limits nitric oxide bioavailability in sickle-cell disease. Nat Med. 2002;8(12):1383-1389. (Pubitemid 36019423)
19. Reiter CD, Gladwin MT. An emerging role for nitric oxide in sickle cell disease vascular homeostasis and therapy. Curr Opin Hematol. 2003;10(2):99-107. (Pubitemid 36207963)
20. Nath KA, Shah V, Haggard JJ, et al. Mechanisms of vascular instability in a transgenic mouse model of sickle cell disease. Am J Physiol Regul Integr Comp Physiol. 2000;279(6):R1949-R1955.
21. Aslan M, Ryan TM, Adler B, et al. Oxygen radical inhibition of nitric oxide-dependent vascular function in sickle cell disease. Proc Natl Acad Sci U S A. 2001;98(26):15215-15220. (Pubitemid 34013994)
22. Gladwin MT, Schechter AN, Ognibene FP, et al. Divergent nitric oxide bioavailability in men and women with sickle cell disease. Circulation. 2003;107(2):271-278. (Pubitemid 36135223)
23. Kaul DK, Liu XD, Chang HY, Nagel RL, Fabry ME. Effect of fetal hemoglobin on microvascular regulation in sickle transgenic-knockout mice. J Clin Invest. 2004;114(8):1136-1145. (Pubitemid 39578703)
24. Furchgott RF, Zawadzki JV. The obligatory role of endothelial cells in the relaxation of arterial smooth muscle by acetylcholine. Nature. 1980;288(5789):373-376. (Pubitemid 11169009)
25. Ignarro LJ, Buga GM, Wood KS, Byrns RE, Chaudhuri G. Endothelium-derived relaxing factor produced and released from artery and vein is nitric oxide. Proc Natl Acad Sci U S A. 1987;84(24):9265-9269.
26. Palmer RM, Ashton DS, Moncada S. Vascular endothelial cells synthesize nitric oxide from L-arginine. Nature. 1988;333(6174):664-666.
27. Panza JA, Casino PR, Kilcoyne CM, Quyyumi AA. Role of endothelium-derived nitric oxide in the abnormal endothelium-dependent vascular relaxation of patients with essential hypertension. Circulation. 1993;87(5):1468-1474. (Pubitemid 23133089)
28. De Caterina R, Libby P, Peng HB, et al. Nitric oxide decreases cytokine-induced endothelial activation: nitric oxide selectively reduces endothelial expression of adhesion molecules and proinflammatory cytokines. J Clin Invest. 1995;96(1):60-68.
29. Cosby K, Partovi KS, Crawford JH, et al. Nitrite reduction to nitric oxide by deoxyhemoglobin vasodilates the human circulation. Nat Med. 2003;9(12):1498-1505. (Pubitemid 38004777)
30. Villagra J, Shiva S, Hunter LA, Machado RF, Gladwin MT, Kato GJ. Platelet activation in patients with sickle disease, hemolysis-associated pulmonary hypertension, and nitric oxide scavenging by cell-free hemoglobin. Blood. 2007;110(6):2166-2172. (Pubitemid 47443936)
31. Martinez-Ruiz R, Montero-Huerta P, Hromi J, Head CA. Inhaled nitric oxide improves survival rates during hypoxia in a sickle cell (SAD) mouse model. Anesthesiology. 2001;94(6):1113-1118. (Pubitemid 32506141)
32. Romero JR, Suzuka SM, Nagel RL, Fabry ME. Arginine supplementation of sickle transgenic mice reduces red cell density and Gardos channel activity. Blood. 2002;99(4):1103-1108. (Pubitemid 34547059)
33. de Franceschi L, Baron A, Scarpa A, et al. Inhaled nitric oxide protects transgenic SAD mice from sickle cell disease-specific lung injury induced by hypoxia/reoxygenation. Blood. 2003;102(3):1087-1096. (Pubitemid 36917810)
34. Fasipe FR, Ubawike AE, Eva R, Fabry ME. Arginine supplementation improves rotorod performance in sickle transgenic mice. Hematology. 2004;9(4):301-305. (Pubitemid 39359352)
35. Dasgupta T, Hebbel RP, Kaul DK. Protective effect of arginine on oxidative stress in transgenic sickle mouse models. Free Radic Biol Med. 2006;41(12):1771-1780. (Pubitemid 44839141)
36. de Franceschi L, Malpeli G, Scarpa A, et al. Protective effects of S-nitrosoalbumin on lung injury induced by hypoxia-reoxygenation in mouse model of sickle cell disease. Am J Physiol Lung Cell Mol Physiol. 2006;291(3):L457- L465. (Pubitemid 44343722)
37. Oppert M, Jörres A, Barckow D, Eckardt KU, Frei U, Kaisers U. Inhaled nitric oxide for ARDS due to sickle cell disease. Swiss Med Wkly. 2004;134(11-12):165-167. (Pubitemid 38418936)
38. Atz AM, Wessel DL. Inhaled nitric oxide in sickle cell disease with acute chest syndrome. Anesthesiology. 1997;87(4):988-990. (Pubitemid 27456256)
39. Sullivan KJ, Goodwin SR, Evangelist J, Moore RD, Mehta P. Nitric oxide successfully used to treat acute chest syndrome of sickle cell disease in a young adolescent. Crit Care Med. 1999;27(11):2563-2568.
40. Head CA, Swerdlow P, McDade WA, et al. Beneficial effects of nitric oxide breathing in adult patients with sickle cell crisis. Am J Hematol. 2010;85(10):800-802.
41. Orringer EP, Casella JF, Ataga KI, et al. Purified poloxamer 188 for treatment of acute vaso-occlusive crisis of sickle cell disease: a randomized controlled trial. JAMA. 2001;286(17):2099-2106. (Pubitemid 34041594)
42. Shiva S, Sack MN, Greer JJ, et al. Nitrite augments tolerance to ischemia/reperfusion injury via the modulation of mitochondrial electron transfer. J Exp Med. 2007;204(9):2089-2102. (Pubitemid 47360871)
43. Duranski MR, Greer JJ, Dejam A, et al. Cytoprotective effects of nitrite during in vivo ischemiareperfusion of the heart and liver. J Clin Invest. 2005; 115(5):1232-1240. (Pubitemid 40629041)
44. Lang JD Jr, Teng X, Chumley P, et al. Inhaled NO accelerates restoration of liver function in adults following orthotopic liver transplantation. J Clin Invest. 2007;117(9):2583-2591. (Pubitemid 47494359)
45. Mathru M, Huda R, Solanki DR, Hays S, Lang JD. Inhaled nitric oxide attenuates reperfusion inflammatory responses in humans. Anesthesiology. 2007; 106(2):275-282. (Pubitemid 46185172)
46. Hataishi R, Rodrigues AC, Neilan TG, et al. Inhaled nitric oxide decreases infarction size and improves left ventricular function in a murine model of myocardial ischemia-reperfusion injury. Am J Physiol Heart Circ Physiol. 2006;291(1):H379-H384.
47. Ballas SK, Lusardi M. Hospital readmission for adult acute sickle cell painful episodes: frequency, etiology, and prognostic significance. Am J Hematol. 2005;79(1):17-25. (Pubitemid 40604787)